Menu
Search
|

Menu

Close
X

Chiasma Inc CHMA.OQ (NASDAQ Stock Exchange Global Select Market)

1.55 USD
-0.05 (-3.12%)
As of 2:29 AM IST
chart
Previous Close 1.60
Open 1.55
Volume 864
3m Avg Volume 10,209
Today’s High 1.55
Today’s Low 1.55
52 Week High 2.95
52 Week Low 1.25
Shares Outstanding (mil) 24.36
Market Capitalization (mil) 70.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
4.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.570
FY16
-2.514
FY15
-1.626
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
0.95
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
2.27
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-34.47
14.43
Return on Equity (TTM)
vs sector
-35.41
16.13

EXECUTIVE LEADERSHIP

David Stack
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Mark Fitzpatrick
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director, Since 2016
Salary: $377,500.00
Bonus: $162,500.00
Drew Enamait
Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller, Since 2016
Salary: $180,622.00
Bonus: $35,000.00
Roni Mamluk
Director, Since 2017
Salary: $284,955.00
Bonus: $118,357.00
Todd Foley
Independent Director, Since 2008
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

460 Totten Pond Rd Ste 530
WALTHAM   MA   02451-1944

Phone: +1617.9285300

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

SPONSORED STORIES